Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to 1847.16%.

  • Fate Therapeutics' EBITDA Margin fell 3370400.0% to 1847.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 2196.67%, marking a year-over-year decrease of 8811500.0%. This contributed to the annual value of 1364.6% for FY2024, which is 11142500.0% down from last year.
  • As of Q3 2025, Fate Therapeutics' EBITDA Margin stood at 1847.16%, which was down 3370400.0% from 1793.34% recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' EBITDA Margin registered a high of 29.96% during Q1 2023, and its lowest value of 5648.02% during Q2 2023.
  • For the 5-year period, Fate Therapeutics' EBITDA Margin averaged around 1419.13%, with its median value being 570.81% (2024).
  • In the last 5 years, Fate Therapeutics' EBITDA Margin crashed by -52348600bps in 2023 and then skyrocketed by 50772100bps in 2024.
  • Quarter analysis of 5 years shows Fate Therapeutics' EBITDA Margin stood at 406.06% in 2021, then surged by 69bps to 123.92% in 2022, then tumbled by -2000bps to 2601.91% in 2023, then dropped by -9bps to 2834.41% in 2024, then skyrocketed by 35bps to 1847.16% in 2025.
  • Its EBITDA Margin was 1847.16% in Q3 2025, compared to 1793.34% in Q2 2025 and 2314.18% in Q1 2025.